$62.14-0.94 (-1.49%)
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally.
Inspire Medical Systems, Inc. in the Healthcare sector is trading at $62.14 with a market capitalization of $1.2B. Wall Street consensus targets $60.40 (15 analysts), implying a -2.8% move over the next 12 months. The stock is currently 58% below its 52-week high of $147.03, remaining 6.0% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $204.58Mβ | $269.08Mβ | $224.50Mβ | $217.09Mβ | $201.32M |
| Gross Profit | $176.91Mβ | $233.01Mβ | $192.73Mβ | $182.41Mβ | $170.61M |
| Operating Income | -$1.12Mβ | $46.11Mβ | $9.64Mβ | -$3.32Mβ | -$1.49M |
| Net Income | -$11.29Mβ | $136.09Mβ | $9.93Mβ | -$3.59Mβ | $2.99M |
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers...

Inspire Medical Systems currently trades at $62.14 per share and has shown little upside over the past six months, posting a small loss of 3.4%. The stock also fell short of the S&P 500βs 11.7% gain during that period.

Inspire (INSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

When Wall Street turns bearish on a stock, itβs worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

Inspire Medical stock's 39.7% three-month surge is driven by the easing of reimbursement pressures, increasing Inspire V adoption and Project Horizon targeting longer-term expansion.